Redeye ser positivt på fredagens viktiga besked om att Lecanemab, under det kommersiella namnet Leqe...
Utfall av företrädesemissionen Bolaget meddelade under veckan utfallet i företrädesemissionen som av...
WntResearch, som genomför en fas 2-studie med läkemedelskandidaten Foxy-5 för patienter som drabbats...
Redeye embraces the FDA Fast Track Designation for the evaluation process of Sedana Medical’s soluti...
Redeye resumes its coverage and comments on the outcome of Acarix’s rights issue.
Endomines reported high-grade drill results significantly below the current production level.
Bricknode announced on Tuesday, January 3rd, that a fund management company (“the Client”) has chose...
Redeye comments on Freemelt’s new order wins and update its estimates for Q4 2022e once again.
Redeye leaves a short comment following Alzinova’s announcement earlier today.
Episurf recently announced that it has received its first product clearance for use on the US market...
Redeye ceases its coverage of Calmark due to the end of the contractual period.
Redeye comments on Sensys Gatso’s recent large orders for its managed-services business.
Redeye comments on Alligator's announcement of the initiation of a second bispecific program within ...
Insurtechbolaget Paydrives intäkter ökade till 6,1 (4,4) miljoner kronor under det tredje kvartalet ...
Calliditas partner in China (including South Korea, Hong Kong, Macau, Taiwan and Singapore) Everest ...
We terminate commissioned coverage on Etteplan. Note that estimates and information have not been up...
Consti is the leading renovation construction company in Finland.
Ferronordic has today sold its Russian business for SEK 1.
MTHH has decided to initiate a sales process for Scandi Byg Market has increasingly been questioning...
Redeye will cease its coverage of Orexo, effective 21st December 2022.
